Related Experiment Videos
Radiolabelled peptides: now and the future
1Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Abstract:
Designed by nature for stimulating, inhibiting or regulating numerous life functions, for a long time peptides have been considered ideal agents for therapeutic applications. In recent years, radiolabelled peptides have emerged as a new, useful class of radiopharmaceuticals for diagnosis of a variety of endocrine tumours. Although clinical results with 111In- and 125I-labelled peptides have been excellent, extensive efforts have been made in preparing and evaluating peptides labelled with 99Tcm. This is the raidonuclide of choice by virtue of its cost-effectiveness, availability and desirable nuclear characteristics. With 99Tcm, certain peptides can be labelled 'directly' without a loss of functional specificity, but certain peptides must be labelled using bifunctional chelating agents. The bifunctional chelating agent methods are chemically complex and frequently inefficient. Instant kit preparations are, however, possible. Important tests in the evaluation of these agents are receptor binding assays as well as examinations in experimental pre-clinical models. Peptides are small and can be taken up in target tissues non-specifically by increased capillary permeability. However, something that is frequently forgotten during such evaluations are control studies with non-specific peptides of similar size and charge. Radiolabelled peptides aimed at instant in vivo interaction with neutrophils or platelets must also be examined carefully to ensure that they do not induce neutropaenia or thrombocytopaenia. The preparation of radiolabelled peptides is not only challenging but also exciting, since these agents will continue to be promising and rewarding radiopharmaceuticals for decades to come.
Insights
Radiolabeled peptides are valuable radiopharmaceuticals for diagnosing endocrine tumors. Technetium-99m (99Tcm) offers advantages for labeling peptides, enabling improved diagnostic imaging and therapeutic applications.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
- Endocrinology
Background:
- Peptides are naturally occurring molecules with diverse biological functions.
- Radiolabeled peptides are emerging as crucial tools in nuclear medicine for diagnostic imaging.
- Technetium-99m (99Tcm) is the preferred radionuclide for peptide labeling due to its favorable characteristics.
Purpose of the Study:
- To review the development and evaluation of radiolabeled peptides for diagnostic applications.
- To highlight the advantages of using 99Tcm for peptide radiolabeling.
- To discuss challenges and considerations in the preparation and preclinical evaluation of these agents.
Main Methods:
- Review of existing literature on radiolabeled peptides.
- Discussion of labeling techniques, including direct labeling and bifunctional chelators.
- Emphasis on receptor binding assays and preclinical models for evaluation.
- Importance of control studies with non-specific peptides.
Main Results:
- Clinical results with 111In- and 125I-labeled peptides have been successful.
- 99Tcm-labeled peptides offer cost-effectiveness, availability, and suitable nuclear properties.
- Both direct labeling and bifunctional chelator methods are employed, with varying efficiencies.
- Preclinical evaluations require rigorous testing, including specificity and safety assessments.
Conclusions:
- Radiolabeled peptides, particularly those labeled with 99Tcm, represent a promising class of radiopharmaceuticals.
- Continued research and development in this area are essential for advancing diagnostic and therapeutic applications.
- Careful evaluation, including control studies and safety assessments, is critical for clinical success.